# Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)

Study · id `cardio:ct-nct05976152` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05976152](<https://clinicaltrials.gov/study/NCT05976152>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05976152

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3200 participants.

## Technical summary

Registry record NCT05976152. Randomized; quadruple masking; primary purpose treatment. Start 2024-04 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3200 participants (planned count; ClinicalTrials.gov record NCT05976152, source copy `cardio:ctgov-nct05976152-2024-04-15`, retrieved 2026-10-26)
- Planned start: 2024-04 (anticipated) (ClinicalTrials.gov record NCT05976152, source copy `cardio:ctgov-nct05976152-2024-04-15`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05976152, source copy `cardio:ctgov-nct05976152-2024-04-15`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05976152, source copy `cardio:ctgov-nct05976152-2024-04-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05976152, source copy `cardio:ctgov-nct05976152-2024-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05976152-2024-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
- Acronym: Be-CLEVER
- Condition: Stroke
- Condition: Post-stroke Cognitive Impairment (PSCI)
- Intervention (Drug): dl-3-butylphthalide
- Intervention (Drug): dl-3-butylphthalide placebo
- Lead sponsor: Fudan University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Fudan University (`cardio:org-fudan-university`)

## Provenance

Content hash: 1761710d7805c9ab9c56bd0d5c84634e7216f109267bdb237e4c4323f97e4989
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
